Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Abstract: The invention relates to compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Abstract: The resent disclosure provides an OLED substrate, a photo mask, and a method of manufacturing the OLED substrate. In one embodiment, an OLED substrate includes: a base substrate; an anode layer on the base substrate; a pixel defining layer on the anode layer, the pixel defining layer having a pattern opening area, the pattern opening area including a plurality of pixel openings arranged in an array manner; and a light-emitting layer formed on the pixel defining layer by evaporation; wherein the pattern opening area has an inward contraction structure with respect to a regular pixel opening area structure in which a plurality of pixel openings are arranged in a manner of an regular array where rows in the regular array are equally spaced from each other and are parallel to each other and columns in the regular array are equally spaced from each other and are parallel to each other.

Abstract: The invention relates to dosage forms for daily administration of compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Abstract: Systems, methods, and computer-readable media for providing cross-domain assurance for networks in different network domains. In some embodiments, a method can include collecting first fabric data for a first network in a first network domain and second fabric data for a second network in a second network domain. The second fabric data for the second network can be normalized based on the first network domain to create normalized second fabric data. The first fabric data can then be correlated with the normalized second fabric data to create correlated fabric data. Subsequently, assurance can be provided across the first network in the first network domain and the second network in the second network domain using the correlated fabric data.

Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Abstract: The invention relates to compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Abstract: Executable files are evaluated for malware in one or more lightweight executors, such as lightweight executor processes. An executable file is loaded and executed in a lightweight executor. Instructions in an execution path of the executable file are executed. Instructions in another execution path of the executable file are executed in another lightweight executor when a conditional branch instruction in an execution path has a suspicious condition. A fake kernel that mimics a real operating system kernel receives system calls, and responds to the system calls without servicing them in a way the real operating system kernel would. Runtime behavior of the executable file is observed for malware behavior. A response action, such as preventing the executable file from subsequently executing in a computer, is performed when the executable file is detected to be malware.

Abstract: Certain embodiments of the invention provide a composition comprising at least two compounds selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the composition is substantially free of flavokawain B. Certain embodiments of the invention also provide a method for treating or preventing cancer in a mammal (e.g., a human) in need of such treatment comprising, administering to the mammal a carrier and a compound selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the compound is substantially free of other kava extract components.

Abstract: The invention provides compounds that are useful for treating or preventing cancer.

Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Abstract: A memory fault detection method includes: receiving a first interrupt signal sent when a count value of a first leaky bucket counter of a server reaches a first threshold; disabling an interrupt switch of the first leaky bucket counter; enabling the interrupt switch of the first leaky bucket counter after the interrupt switch of the first leaky bucket counter has been disabled for a preset time and the count value of the first leaky bucket counter is reset to zero; receiving a second interrupt signal sent when a count value of a second leaky bucket counter reaches a second threshold; if the second leaky bucket counter and the first leaky bucket counter are a same leaky bucket counter, and the second rank and a first rank are a same rank, determining that a hardware fault occurs in the first rank.

Abstract: The disclosure discloses an organic light-emitting diode display substrate, a method for fabricating the same, an organic light-emitting diode display panel, and a display device. Since display brightness is required of a top-emitting organic light-emitting diode element with a large size, the resistance of a cathode should not be too large, so the cathode should be made with a large thickness, but if the thickness of the cathode is too large, then a light exit ratio of the element may be degraded. Accordingly in the embodiments of the disclosure, cathodes can be formed in a grid structure to thereby guarantee a high light exit ratio while guaranteeing display brightness thereof; and the cathodes are made of a metal nanometer material.

Abstract: Provided herein are novel compounds and pharmaceutically acceptable salts thereof that are liver X receptor modulators. Also provided are compositions comprising compounds of the invention and a carrier. Additionally, use of the compounds herein and methods for treating a disease or disorder associated with the liver X receptor are further described.

Abstract: Certain embodiments of the invention provide a composition comprising at least two compounds selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the composition is substantially free of flavokawain B. Certain embodiments of the invention also provide a method for treating or preventing cancer in a mammal (e.g., a human) in need of such treatment comprising, administering to the mammal a carrier and a compound selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the compound is substantially free of other kava extract components.

Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Abstract: The invention provides compounds that are useful for treating or preventing cancer.

Abstract: The invention that relates to the field of hydropower scheduling presents a method for long-tens optimal operations of interprovincial hydropower system considering peak-shaving demands. It can take full advantage of the differences of hydrological characteristics among hydropower plants on different rivers to implement compensation operations of interprovincial hydropower system. In this operation, typical daily load demands during dry season are considered to optimize the allocation of hydropower production over one year. The purpose is to increase the dispatchable generation capacity for peak demands of power grids. The technology scheme of the invention can be summarized as follows. A multi-objective model of hydropower system operations is established with maximizing generation production and minimizing the difference rate between peak and valley load during dry period.